An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer

Title:An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer

Volume: 14 Issue: 12

Author(s): Eliza de Lucas Chazin, Raisa da Rocha Reis, Walcimar Trindade Vellasco Junior, Lucas Fajardo Elmor Moor and Thatyana Rocha Alves Vasconcelos

Affiliation:

Keywords: Camptothecin, cancer, drugs, homocamptothecin, irinotecan, topoisomerase inhibitors, topotecan.

Abstract: Camptothecin (CPT) and its derivatives comprise an important group of heterocyclic compounds that are well recognized for their anticancer activities. Efforts have been made over the years aiming to develop new CPT analogs with better clinical efficacy, improved pharmacokinetic profile and lower toxicity. First generation of analogs, irinotecan (CPT-11) and topotecan (TPT) was approved for use by FDA in 1996 for the treatment of colorectal (CPT-11) and cervical, ovarian and small lung cancers (TPT). Other analogs of CPT are currently in different phases of clinical trials. As CPT represents an important lead compound in the field of antitumor- research, in this review we will highlight some recent discoveries (2008-2013) on the development of novel camptothecin-based compounds as potential anticancer agents.

Cite this article as:

Chazin de Lucas Eliza, Reis da Rocha Raisa, Junior Trindade Vellasco Walcimar, Moor Fajardo Elmor Lucas and Vasconcelos Rocha Alves Thatyana, An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer, Mini-Reviews in Medicinal Chemistry 2014; 14 (12) . https://dx.doi.org/10.2174/1389557514666141029233037